Delivery System For Ayahuasca-Like Substances

Abstract

Provided herein is a delivery device and vaporizable formulations that provide users or patients with the ability to safely, reliably, and conveniently obtain a high-quality, therapeutic vapor comprising an ayahuasca-like substance. The delivery device includes a chamber coupled to a power unit capable of providing power to vaporize the formulations for consumption of the substance in a consistently desirable and safe manner. Further included are kits and methods of treating psychological disorders using the delivery device and vaporizable formulations provided herein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation under 35 USC 365(c) of International Application No. PCT / US21 / 42123, filed Jul. 18, 2021, which claims priority benefit to U.S. Provisional Application No. 63 / 058,444, filed Jul. 29, 2020, and U.S. Provisional Application No. 63 / 144,923, filed Feb. 2, 2021, the entire contents of each of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION[0002]In certain jurisdictions, ayahuasca-like substances and other psychedelic medicines are being legalized or decriminalized, hence allowing for breakthrough alternative medicines and / or recreational experiences. Psychedelic research is still in its infancy, which in part is a consequence of legal barriers to such research that has existed for decades. Yet preliminary reports are encouraging. For example, it was recently reported that dimethyltryptamine, which is the active ingredient in ayahuasca, can promote the proliferation of neural stem cells ...

AI Technical Summary

Benefits of technology

The patent describes a system for delivering a vaporizable formulation containing an ayahuasca-like substance. The system includes a chamber with a top portion that can be connected to a mouthpiece. The chamber has an aperture that allows air, liquid, solids, or vapor to flow through it. The mouthpiece has an aperture, a central open bore, and a bottom portion with an aperture. The system also includes a bottom portion that can be connected to a power unit to vaporize the vaporizable formulation. The system can be reusable or single-use. The patent also describes the composition of the vaporizable formulation, which includes dimethyltryptamine and a monoamine oxidase inhibitor. The system allows for the safe and controlled delivery of the ayahuasca-like substance for therapeutic purposes.

Problems solved by technology

Psychedelic research is still in its infancy, which in part is a consequence of legal barriers to such research that has existed for decades.

However, the ability to distribute reliably consistent amounts and types of ayahuasca-like substances having a particular level of therapeutic or recreational quality is limited.

Safety concerns may also arise when ayahuasca-like substances are obtained in a manner where the exact composition is unknown due to risks of contamination, tampering, misrepresentation, etc.

Images